Literature DB >> 14698702

Validation of the quality of life in childhood epilepsy questionnaire in American epilepsy patients.

Mark Sabaz1, John A Lawson, David R Cairns, Michael S Duchowny, Trevor J Resnick, Patricia M Dean, Ann M E Bye.   

Abstract

The aim of this study was to adapt the Australian Quality of Life in Childhood Epilepsy Questionnaire (QOLCE) and determine its psychometric properties in a North American population. Participants were North American families with children diagnosed with epilepsy. Parents were asked to complete the American QOLCE (USQOLCE) and the Child Health Questionnaire (CHQ). Seventy-one families completed the USQOLCE. The internal consistency reliability of the subscales was good. USQOLCE subscales correlated highly with theoretically similar subscales contained in the CHQ. Theoretically dissimilar subscales on the two instruments did not correlate as well. USQOLCE correlated significantly with a parental rating of seizure severity and an independent measure of degree of postoperative seizure control. This study demonstrated that the USQOLCE is suitable for a North American population with evidence of its reliability and validity including its sensitivity to seizure burden.

Entities:  

Mesh:

Year:  2003        PMID: 14698702     DOI: 10.1016/j.yebeh.2003.08.012

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  31 in total

1.  Treatment factors affecting longitudinal quality of life in new onset pediatric epilepsy.

Authors:  Avani C Modi; Lisa M Ingerski; Joseph R Rausch; Tracy A Glauser
Journal:  J Pediatr Psychol       Date:  2011-01-29

2.  Examining clinically relevant levels of depressive symptoms in mothers following a diagnosis of epilepsy in their children: a prospective analysis.

Authors:  Mark Anthony Ferro; Kathy Nixon Speechley
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2011-11-09       Impact factor: 4.328

3.  Functional Connectivity Associated with Health-Related Quality of Life in Children with Focal Epilepsy.

Authors:  H Nawani; M L Smith; A L Wheeler; E Widjaja
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-20       Impact factor: 3.825

4.  Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol.

Authors:  Evan C Rosenberg; Jay Louik; Erin Conway; Orrin Devinsky; Daniel Friedman
Journal:  Epilepsia       Date:  2017-06-15       Impact factor: 5.864

5.  Do depressive symptoms affect mothers' reports of child outcomes in children with new-onset epilepsy?

Authors:  Mark A Ferro; William R Avison; M Karen Campbell; Kathy N Speechley
Journal:  Qual Life Res       Date:  2010-05-07       Impact factor: 4.147

6.  Care-related quality of life in caregivers of children with drug-resistant epilepsy.

Authors:  Puneet Jain; Jhananiee Subendran; Mary Lou Smith; Elysa Widjaja
Journal:  J Neurol       Date:  2018-07-20       Impact factor: 4.849

7.  Supporting Treatment Adherence Regimens in young children with epilepsy and their families: Trial design and baseline characteristics.

Authors:  Avani C Modi; Tracy A Glauser; Shanna M Guilfoyle
Journal:  Contemp Clin Trials       Date:  2020-02-14       Impact factor: 2.226

8.  Quality of life in childhood epilepsy with lateralized epileptogenic foci.

Authors:  Krystyna A Mathiak; Małgorzata Luba; Klaus Mathiak; Katarzyna Karzel; Tomasz Wolańczyk; Elzbieta Szczepanik; Paweł Ostaszewski
Journal:  BMC Neurol       Date:  2010-08-17       Impact factor: 2.474

9.  Predictors of trajectories of epilepsy-specific quality of life among children newly diagnosed with epilepsy.

Authors:  Rachelle R Ramsey; Kristin Loiselle; Joseph R Rausch; Jordan Harrison; Avani C Modi
Journal:  Epilepsy Behav       Date:  2016-03-12       Impact factor: 2.937

10.  Factor structure of the Child Health Questionnaire Parent Form-50 and predictors of health-related quality of life in children with epilepsy.

Authors:  Mark A Ferro; Jeanne M Landgraf; Kathy N Speechley
Journal:  Qual Life Res       Date:  2013-01-20       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.